|
業務類別
|
Biotechnology |
|
業務概覽
|
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system. |
| 公司地址
| 3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247 |
| 電話號碼
| +1 214 612-0000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.tayshagtx.com |
| 員工數量
| 99 |
| Mr. Sean P. Nolan |
Chairman of the Board and Chief Executive Officer |
美元 645.84K |
22/04/2026 |
| Dr. Sukumar Nagendran, M.D. |
Director, President and Head, Research and Development |
美元 608.17K |
22/04/2026 |
| Mr. Kamran Alam, C.P.A. |
Corporate Secretary, Chief Financial Officer and Principal Accounting Officer |
美元 473.33K |
22/04/2026 |
|
|
| Mr. Phillip B. Donenberg |
Independent Director |
22/04/2026 |
| Mr. Sean P. Nolan |
Chairman of the Board and Chief Executive Officer |
22/04/2026 |
| Mr. Sean Stalfort |
Independent Director |
22/04/2026 |
| Dr. Sukumar Nagendran, M.D. |
Director, President and Head, Research and Development |
22/04/2026 |
| Dr. Laura Sepp-Lorenzino, PhD |
Independent Director |
22/04/2026 |
| Dr. Alison S. Long, M.D.,PhD |
Independent Director |
22/04/2026 |
|
|
|
|
